Neurocrine To Acquire Soleno For $2.9 Bln Cash Deal; Soleno Stock Surges In Pre-market

Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $53 per share in cash, valuing Soleno at approximately $2.9 billion. The all-cash $2.9B deal is a material biotech M&A transaction that will directly move the two companies' equities and has strategic implications for Neurocrine's product portfolio.

Analysis

Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $53 per share in cash, valuing Soleno at approximately $2.9 billion. The all-cash $2.9B deal is a material biotech M&A transaction that will directly move the two companies' equities and has strategic implications for Neurocrine's product portfolio.